Comparative Pharmacology
Head-to-head clinical analysis: BENZONATATE versus PHERAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZONATATE versus PHERAZINE DM.
BENZONATATE vs PHERAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Phererazine DM is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic properties) and dextromethorphan (a non-opioid antitussive that acts on the sigma-1 receptor and NMDA receptor antagonist). Promethazine blocks H1 receptors and reduces histamine-mediated symptoms, while dextromethorphan suppresses cough by central action on the cough center.
100 mg to 200 mg orally three times daily as needed for cough.
Adults: 1 tablet (promethazine 25 mg / dextromethorphan 30 mg) orally every 6-8 hours as needed; maximum 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life: 3-4 hours in children; 5-6 hours in adults; up to 8 hours in elderly. Clinical context: Dosing interval adjustment needed in renal impairment.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Primarily renal: 60-70% as unchanged drug and glucuronide conjugate; 15-20% fecal via biliary excretion.
Category A/B
Category C
Antitussive
Antitussive/Antihistamine Combination